News Releases
-
-
Vetter continues to implement its long-term sustainability strategy
Minister of Transport praises the commitment of the pharmaceutical service provider during global turbulent timesReleased by: Vetter Pharma International
-
Syngene and Deerfield Discovery and Development (3DC) sign 5-year strategic collaboration
...Released by: Syngene
-
CCRM and McMaster Innovation Park (MIP) Partner to Build and Operate Biomanufacturing Campus
...Released by: CCRM
-
-
Syngene International Q2 profit up 64 pc to Rs 128 cr
Press Trust of India | New DelhiReleased by: Syngene
-
Vetter continues its long-term investment strategy to sustain future growth
Existing buildings are repurposed as others continue to be built and recently housedReleased by: Vetter Pharma International
-
Syngene joins global consortium to accelerate research in COVID-19 testing
The consortium brings together a diverse group of companies with synergistic areas of expertiseReleased by: Syngene
-
-
Kohlberg and Mubadala sign a definitive agreement to acquire majority stake in PCI Pharma Services
...Released by: PCI Pharma Services
-
A strong signal in turbulent times: Vetter achieves carbon dioxide-neutral levels
Contract Development and Manufacturing Organization further expands its commitment to climate protectionReleased by: Vetter Pharma International
-
PCI Pharma Services Announces Global Expansion of Clinical Trial Services
PCI Broadens Global Clinical Supply-Chain Service Offerings Into Mainland EuropeReleased by: PCI Pharma Services
-
Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration
to Develop Emergent’s COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Department of Defense FundingReleased by: Emergent BioSolutions
-
Vetter further expands its Development Service with new site in Austria
With the new Vetter Development Service Rankweil site in Austria, Vetter expands its European footprint.Released by: Vetter Pharma International
-
Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing
for Johnson & Johnson’s Lead COVID-19 Vaccine CandidateReleased by: Emergent BioSolutions
-
The key to tackling drug development complexity: Collaboration.
Rentschler Biopharma and Vetter team up with joint goal to simplify processes and optimize time-to-marketReleased by: Vetter Pharma International
-
Multimillion Dollar Investment Firmly Establishes Commercial Operations Globally to Support Business
PCI Pharma Services Announces Completion of Biotech Center of Excellence in Philadelphia and Expansions to Biotech Capabilities in EuropeReleased by: PCI Pharma Services
-
Emergent BioSolutions to Invest $75 Million
in Canton Site and Expand Viral Vector and Gene Therapy CapabilityReleased by: Emergent BioSolutions
-
Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner
for AstraZeneca’s COVID-19 Vaccine CandidateReleased by: Emergent BioSolutions
-
Flow Sciences, Inc. Supplies 10 Enclosures for High Capacity COVID-19 Testing
Personnel protection was required while processing virus samplesReleased by: Flow Sciences
